Clinical trials
Estrogen Receptor-Positive Breast Carcinoma clinical trials
Below are recruiting estrogen receptor-positive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05464810RecruitingEarly Phase 1
Letrozole with or without a cholesterol drug for early breast cancer
This early-phase study tests whether adding simvastatin to letrozole can improve outcomes in people with stage I–III breast cancer that grows with hormone signals (hormone receptor positive) and does not have HER2. It looks mainly at whether the approach is safe and useful for this specific breast cancer type.
Atlanta, GeorgiaAges 18 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT07762885RecruitingPhase 3
Comparing skipping radiation after surgery for early-stage DCIS
This trial compares skipping radiation therapy after breast-conserving surgery for low- or intermediate-risk ductal carcinoma in situ (DCIS) – a very early, non-invasive breast cancer. It aims to see if omitting radiation is as effective as standard treatment while reducing side effects.
ShanghaiAges 40 years+ - NCT06222957Recruiting
How HER2 affects brown fat in breast cancer patients
This study looks at how a protein called HER2 affects brown fat activity in women with breast cancer. Brown fat helps burn calories and may influence treatment outcomes. You will be assigned to one of two groups based on your cancer's HER2 status, and the study will measure how your brown fat responds to cold.
CopenhagenAges 18 years+
Hear when a new Estrogen Receptor-Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for estrogen receptor-positive breast carcinoma?
- Yes. Clin2 currently lists 29 recruiting estrogen receptor-positive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a estrogen receptor-positive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a estrogen receptor-positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hormone Receptor Positive Breast Carcinoma
- Estrogen-receptor-positive Breast Cancer
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HER2 Positive Breast Carcinoma
- Estrogen Receptor Positive Tumor
- Hormone Receptor Negative Breast Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.